Compare Apartment Investment and Management Co (AIV) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apartment Investment and Management Co vs Vertex Pharmaceuticals Incorporated — how do they compare? Apartment Investment and Management Co trades at $2.62 (market cap $376.16M), while Vertex Pharmaceuticals Incorporated trades at $526 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 356.9× Apartment Investment and Management Co's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| AIV | VRTX | |
|---|---|---|
Market Cap | $376.16M | $134.25B |
Sector | Real Estate | Health |
52-Week High | $7.93 | $529.65 |
52-Week Low | $2.59 | $376.62 |
Enterprise Value | $738.32M | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.605, down 0.57% today, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q1 and Q4 2025 but missing in Q2 and Q3. Despite a net income margin of 400.05% in 2025, revenue declined to $138.49M from $209M in 2024. Analyst consensus shows 1 Buy and 2 Hold ratings, indicating cautious optimism. A dividend of $1.30 is scheduled for H1-2026.
Outlook: AIV's high profitability metrics and undervalued P/B ratio of 0.76 present potential upside, but declining revenue and bearish technicals pose risks. Investment opportunity lies in dividend yield and earnings recovery, while key risks include revenue volatility and competitive pressures in real estate.
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
